Extended Data Table 4 Proportion of patients responding to EORTC QLQ-C15-PAL The table shows the proportion of patients that responded to the quality of life item in the EORTC QLQ-C15-PAL questionnaire at each of the protocol-defined time points, as a percentage of all patients who remained in the study until that time point

From: Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial